Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience

Ashok Jain, Mike Nalesnik, Jorge Reyes, Renu Pokharna, George Mazariegos, Michael Green, Bijan Eghtesad, Wallis Marsh, Thomas Cacciarelli, Paulo Fontes, Kareem Abu-Elmagd, Rakesh Sindhi, Jake Demetris, John Fung, Paul S. Russell, Stephen T. Bartlett, John S. Najarian

Research output: Contribution to journalArticle

171 Scopus citations

Abstract

Objective: To evaluate the incidence of posttransplant lymphoproliferative disease (PTLD) and the risk factors and the impact of this complication on survival outcomes in a large cohort of liver transplant recipients at a single institution. Summary Background Data: Liver transplantation has been accepted as a therapeutic option for patients with end-stage liver disease since 1983, in large part due to the availability and reliance on the use of nonspecifically directed immunosuppression. However, as predicted and subsequently verified in 1968, an increased incidence of certain de novo malignancies has been observed, particularly with regards to lymphoid neoplasms. While many reports have confirmed and clarified the nature of PTLD, the literature is fraught with conflicting experience and outcomes with PTLD. Methods: Four thousand consecutive patients who underwent liver transplants between February 1981 and April 1998 were included in this analysis and were followed to November 2001. The effect of recipient age at the time of transplant, recipient gender, diagnosis, baseline immunosuppression, grading of PTLD, and association with Epstein-Barr virus were compared. The causes of death were also examined. Treatment for PTLD varied over the 20-year period, but all included massive reduction or elimination of baseline immunosuppression. Results: The 1-year patient survival for liver transplant patients with PTLD was 85%, while the overall patient survival for the entire cohort was 53%. The actuarial 20-year survival was estimated at 45%. The overall median time to PTLD presentation was 10 months, and children had an incidence of PTLD that was threefold higher than adults. Patient survival was better in children, in patients transplanted in the era of tacrolimus immunosuppression, in patients with polymorphic PTLD, and in those with limited disease. Interestingly, neither the presence or absence of Epstein-Barr virus nor the timing of PTLD presentation appeared to influence overall patient survival. Patients transplanted for alcohol-related liver disease had a similar incidence of PTLD but had a higher risk of mortality. Conclusions: While PTLD continues to pose problems in patients receiving liver transplants, improvements in patient survival have been observed over time. While it is too early to assess the impact of new advances in prophylaxis, diagnosis, and treatment, such approaches are based on an increased knowledge of the pathophysiology of PTLD.

Original languageEnglish (US)
Pages (from-to)429-437
Number of pages9
JournalAnnals of surgery
Volume236
Issue number4
DOIs
StatePublished - Oct 1 2002

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint Dive into the research topics of 'Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience'. Together they form a unique fingerprint.

  • Cite this

    Jain, A., Nalesnik, M., Reyes, J., Pokharna, R., Mazariegos, G., Green, M., Eghtesad, B., Marsh, W., Cacciarelli, T., Fontes, P., Abu-Elmagd, K., Sindhi, R., Demetris, J., Fung, J., Russell, P. S., Bartlett, S. T., & Najarian, J. S. (2002). Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Annals of surgery, 236(4), 429-437. https://doi.org/10.1097/00000658-200210000-00005